

## Real World Outcomes across the AD spectrum for better care: Multi-modal Data Access Platform


Frédéric de Reydet de Vulpillieres<sup>1</sup>, Martin Pan<sup>2</sup>, Carlos Diaz<sup>3</sup>, Johan Van der Lei<sup>4</sup>, John Gallacher<sup>5</sup>

1. Novartis 2. Biogen 3. Synapse 4. Erasmus University 5. University of Oxford

Innovative treatments are needed to **improve treatment options for patients** and address the economic, caregiver and societal impact of AD


- ROADMAP is an IMI funded Public Private Partnership bringing together a wide range of academic and industry partners from across Europe
- ROADMAP aims to provide Europe wide integrated data environment and framework for real world evidence across the spectrum of Alzheimer's disease

ROADMAP provides a **comprehensive approach to real world evidence** through a systematic programme of work




ROADMAP provides **access to multiple diverse datasets**

- ROADMAP uses existing informatics infrastructures (EMIF and DPUK) for data access
- ROADMAP uses a data pyramid model to provide a comprehensive evidence base



ROADMAP uses a **data cube model** to integrate data sources in relation to disease stage and outcome

- ROADMAP will populate the data cube to inform the selection of testable disease models



ROADMAP uses realistically complex **use-cases** to develop scalable and transferable solutions

- ROADMAP will use a variety of methods and approaches to inform clinical decision making

